Wutah pendapatan taun lumaku: Incyte Pharma (INCY)

Logo perusahaan publik incyte.com (INCY)

Incyte Corporation (INCY) profitability is based on the success of Jakafi and growth in the dermatology segment. Comparative year-over-year sales dynamics over a rolling period visualize this trend, where the latest value is recorded as 24.90. A monopoly in the treatment of rare hematological diseases makes the company an indispensable alternative. Meanwhile, the expansion of drug indications scales profits, effectively offsetting R&D costs.

Incyte Corporation (INCY): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Incyte Corporation - rincian analitis lan metrik utama (INCY)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Incyte Corp.
Produk merek Incyte Pharma

For Incyte Corporation (INCY), which is currently in a phase of stabilizing revenues from its core oncology drugs, this metric serves as an indicator of portfolio diversification efficiency. By analyzing the last twelve months (LTM) growth rate of commercial revenue, an investor assesses the increase in aggregate sales over a rolling twelve-month period, which helps neutralize quarterly volatility and determine whether new dermatological products are offsetting the stagnation of previous cycles.

Karo sapa Incyte Corporation saingan

HUTCHMED Ltd (HCM) - Wutah pendapatan taun lumaku|NUVB - Wutah dodolan YoY sajrone rolas wulan kepungkur|Wutah pendapatan taun lumaku Day One|MNPR: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Inhibrx Biosciences Inc INBX|Wutah pendapatan YoY sajrone 12 wulan kepungkur IMAB|Wutah pendapatan taun lumaku Fennec Pharmaceuticals FENC|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur